Literature DB >> 29669730

Drug-Induced Alterations of Mitochondrial DNA Homeostasis in Steatotic and Nonsteatotic HepaRG Cells.

Dounia Le Guillou1, Simon Bucher1, Karima Begriche1, Delphine Hoët1, Anne Lombès1, Gilles Labbe1, Bernard Fromenty2.   

Abstract

Although mitochondriotoxicity plays a major role in drug-induced hepatotoxicity, alteration of mitochondrial DNA (mtDNA) homeostasis has been described only with a few drugs. Because it requires long drug exposure, this mechanism of toxicity cannot be detected with investigations performed in isolated liver mitochondria or cultured cells exposed to drugs for several hours or a few days. Thus, a first aim of this study was to determine whether a 2-week treatment with nine hepatotoxic drugs could affect mtDNA homeostasis in HepaRG cells. Previous investigations with these drugs showed rapid toxicity on oxidative phosphorylation but did not address the possibility of delayed toxicity secondary to mtDNA homeostasis impairment. The maximal concentration used for each drug induced about 10% cytotoxicity. Two other drugs, zalcitabine and linezolid, were used as positive controls for their respective effects on mtDNA replication and translation. Another goal was to determine whether drug-induced mitochondriotoxicity could be modulated by lipid overload mimicking nonalcoholic fatty liver. Among the nine drugs, imipramine and ritonavir induced mitochondrial effects suggesting alteration of mtDNA translation. Ritonavir toxicity was stronger in nonsteatotic cells. None of the nine drugs decreased mtDNA levels. However, increased mtDNA was observed with five drugs, especially in nonsteatotic cells. The mtDNA levels could not be correlated with the expression of key factors involved in mitochondrial biogenesis, such as peroxisome proliferator-activated receptor-γ coactivator 1α (PGC1α), PGC1β, and AMP-activated protein kinase α-subunit. Hence, drug-induced impairment of mtDNA translation might not be rare, and increased mtDNA levels could be a frequent adaptive response to slight energy shortage. Nevertheless, this adaptation could be impaired by lipid overload.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29669730     DOI: 10.1124/jpet.117.246751

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

Review 1.  Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models.

Authors:  Richard J Weaver; Eric A Blomme; Amy E Chadwick; Ian M Copple; Helga H J Gerets; Christopher E Goldring; Andre Guillouzo; Philip G Hewitt; Magnus Ingelman-Sundberg; Klaus Gjervig Jensen; Satu Juhila; Ursula Klingmüller; Gilles Labbe; Michael J Liguori; Cerys A Lovatt; Paul Morgan; Dean J Naisbitt; Raymond H H Pieters; Jan Snoeys; Bob van de Water; Dominic P Williams; B Kevin Park
Journal:  Nat Rev Drug Discov       Date:  2019-11-20       Impact factor: 84.694

2.  The GOLIATH Project: Towards an Internationally Harmonised Approach for Testing Metabolism Disrupting Compounds.

Authors:  Juliette Legler; Daniel Zalko; Fabien Jourdan; Miriam Jacobs; Bernard Fromenty; Patrick Balaguer; William Bourguet; Vesna Munic Kos; Angel Nadal; Claire Beausoleil; Susana Cristobal; Sylvie Remy; Sibylle Ermler; Luigi Margiotta-Casaluci; Julian L Griffin; Bruce Blumberg; Christophe Chesné; Sebastian Hoffmann; Patrik L Andersson; Jorke H Kamstra
Journal:  Int J Mol Sci       Date:  2020-05-14       Impact factor: 5.923

3.  Molecular Networking for Drug Toxicities Studies: The Case of Hydroxychloroquine in COVID-19 Patients.

Authors:  Pierre-Jean Ferron; Brendan Le Daré; Julie Bronsard; Clara Steichen; Elodie Babina; Romain Pelletier; Thierry Hauet; Isabelle Morel; Karin Tarte; Florian Reizine; Bruno Clément; Bernard Fromenty; Thomas Gicquel
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

Review 4.  Xenobiotic-Induced Aggravation of Metabolic-Associated Fatty Liver Disease.

Authors:  Julie Massart; Karima Begriche; Anne Corlu; Bernard Fromenty
Journal:  Int J Mol Sci       Date:  2022-01-19       Impact factor: 5.923

5.  Essential phospholipids decrease apoptosis and increase membrane transport in human hepatocyte cell lines.

Authors:  Dominik Wupperfeld; Gert Fricker; Béatrice Bois De Fer; Larissa Frank; Annika Wehrle; Branko Popovic
Journal:  Lipids Health Dis       Date:  2022-09-24       Impact factor: 4.315

Review 6.  Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury?

Authors:  Pierre-Jean Ferron; Thomas Gicquel; Bruno Mégarbane; Bruno Clément; Bernard Fromenty
Journal:  Biochimie       Date:  2020-09-03       Impact factor: 4.079

7.  New insights into quetiapine metabolism using molecular networking.

Authors:  Brendan Le Daré; Pierre-Jean Ferron; Pierre-Marie Allard; Bruno Clément; Isabelle Morel; Thomas Gicquel
Journal:  Sci Rep       Date:  2020-11-16       Impact factor: 4.379

8.  The utility of a differentiated preclinical liver model, HepaRG cells, in investigating delayed toxicity via inhibition of mitochondrial-replication induced by fialuridine.

Authors:  Carol E Jolly; Oisin Douglas; Laleh Kamalian; Rosalind E Jenkins; Alison J Beckett; Sophie L Penman; Dominic P Williams; Mario Monshouwer; Damir Simic; Jan Snoeys; B Kevin Park; Amy E Chadwick
Journal:  Toxicol Appl Pharmacol       Date:  2020-07-28       Impact factor: 4.219

Review 9.  Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update.

Authors:  Laura Giuseppina Di Pasqua; Marta Cagna; Clarissa Berardo; Mariapia Vairetti; Andrea Ferrigno
Journal:  Biomedicines       Date:  2022-01-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.